A5024101704- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Cancer Genomics and Diagnostics
- Galectins and Cancer Biology
- Multiple and Secondary Primary Cancers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Biomedical Text Mining and Ontologies
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- Neutropenia and Cancer Infections
- Immunodeficiency and Autoimmune Disorders
Rigshospitalet
2022-2025
Copenhagen University Hospital
2024-2025
Danish Cancer Society
2024-2025
University of Copenhagen
2024
Gentofte Hospital
2018
Lymphoid-lineage cancers (LC; International Classification of Diseases, 10th edition [ICD10] C81.x-C90.x, C91.1-C91.9, C95.1, C95.7, C95.9, D47.2, D47.9B, and E85.8A) share many epidemiological clinical features, which favor meta-learning when developing medical artificial intelligence (mAI). However, access to large, shared datasets is largely missing limits mAI research. Creating a large-scale data repository for patients with LC develop data-driven hematology. We gathered electronic...
The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. CLL-CI based on assessment of organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at time initiation CLL therapy. categorizes patients into low, intermediate, high risk groups. In present study, we have employed a population-based cohort comprising 4975 CLL. We...
An increased risk of developing atrial fibrillation (AF) has been observed in patients with chronic lymphocytic leukemia (CLL) who were treated ibrutinib and other BTK inhibitors. Previous studies have explored the prevalence AF CLL at time diagnosis. However, interaction between treatment type factors on initiation not investigated. This becomes particularly crucial CLL, as there is often a substantial gap diagnosis treatment, unlike many cancers. We propose treatment-aware approach using...
For chronic lymphocytic leukaemia (CLL), targeted drugs have become the standard of care, in particular for second-line treatment. In this study, overall survival (OS), treatment-free (TFS) and adverse events (AE) were registered retrospectively a Danish population-based cohort upon treatment CLL. Data collected from medical records National CLL register. 286 patients receiving treatment, three-year TFS was higher (ibrutinib/venetoclax/idelalisib) [63%, 95% confidence interval (CI) 50%-76%]...
Abstract Age‐related comorbid conditions are exceedingly common in patients with chronic lymphocytic leukemia (CLL). As the prevalence of type 2 diabetes (T2D) is predicted to double during next two decades, a better understanding interplay between CLL and T2D increasing importance. In this study, analyses were performed parallel separate cohorts, based on Danish national registers Mayo Clinic Resource. The primary outcomes overall survival (OS) from time diagnosis, OS treatment, first...
Lymphoid-lineage cancers (LC: lymphoma, chronic lymphocytic leukemia, multiple myeloma, and their precursors) share many epidemiological clinical features. To develop data-driven hematology, we gathered electronic health data created open-source processing pipelines to create a comprehensive resource for Danish LC Research (DALY-CARE) approved epidemiological, molecular, research. We included all adults registered with diagnoses since 2002 (n=65,774) combined 10 nationwide registers, records...
Background: Because of a generally advanced age at diagnosis chronic lymphocytic leukemia (CLL), this group patients is often burdened by comorbid conditions. Comorbid conditions are associated with increased mortality in CLL, due to causes both related and unrelated CLL. Diabetes one the most common prevalence 8-21% time CLL-diagnosis, diabetes projected double general population within next two decades. While many may have limited potential for improvement management, treatment type 2...